Alkermes, Inc. (NASDAQ:ALKS)
| CAPS Rating |
|
|---|---|
| Open | $18.33 |
| Previous Close | $18.47 |
| Daily Range | $17.90 - $18.33 |
| 52-Week Range | $11.86 - $20.00 |
| Market Cap | $1.76B |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 798,497 |
| Average Daily Volume | 0 |
ALKS
VS S&P 500 (SPY)
How do you think ALKS will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
ALKS Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
ALKS News and Commentary
- Novo Nordisk Posts Solid 4Q - Analyst Blog – NASDAQ
- Alkermes Beats Up on Analysts Yet Again – The Motley Fool
- The Zacks Analyst Blog Highlights: Alkermes plc, Elan, Johnson & Johnson, Amylin Pharmaceuticals and – NASDAQ
- Revenues Skyrocket at Merged Alkermes - Analyst Blog – NASDAQ
- Has Elan Become the Perfect Stock? – The Motley Fool
- New Study for Alkermes' Vivitrol - Analyst Blog – NASDAQ
- Zyprexa Pulls Down Lilly's 4Q Sales - Analyst Blog – NASDAQ
- FDA Approves Amylin Diabetes Drug – Blogs @ The Motley Fool
- An Approval. Finally. – The Motley Fool
- US Stocks Edge Lower As Europe's Debt Flashpoints Weigh – SmartMoney
- Third Time Lucky for Amylin's Bydureon - Analyst Blog – NASDAQ
- Amylin Shares Rise on Diabetes Drug Approval, Challenges Loom – Minyanville
- US Stock Futures Lower On Renewed Worries Over Greece – SmartMoney
- Amylin Pharmaceuticals Motto: Try, Try, and then Try Again – Blogs @ The Motley Fool
- 2nd UPDATE: FDA Approves Amylin's Bydureon Diabetes Drug After Delays – SmartMoney
- UPDATE: FDA Approves Amylin's Bydureon Diabetes Drug After Delays – SmartMoney
- FDA Approves Amylin's Bydureon Diabetes Drug After Delays – SmartMoney
- Will Bydureon Gain FDA Approval? – The Motley Fool
- Good News for Alkermes' Pipeline - Analyst Blog – NASDAQ
- What Will Elan Do for an Encore? – The Motley Fool
RSS Headlines
Fool UK
